Kelajakdagi narxning foydaga nisbati: xenon-pharma.com (XENE)

Xenon Corp (XENE) tovar belgisi

Xenon Pharmaceuticals (XENE) surishishga qarshi dori vositalarini ishlab chiqadi, ularning surunkali tabiati barqaror pul oqimini kafolatlaydi. Biznesning forward P/E koeffitsiyenti bozor shovqinlarini yumshatadi, bunda 0.00 belgisi joriy ko'rsatkich vazifasini o'taydi. Xenon Pharmaceuticals global markaziy nerv tizimi bozori uchun selektiv ion kanallari blokatorlariga e'tibor qaratgan holda, shifokorlarning yuqori ishonchi bilan tan olingan innovator maqomini saqlab qolmoqda.

Prognoz qilingan narx-foyda nisbati: Xenon (XENE) 04.07.2022 - 17.11.2026 uchun

xenon-pharma.com (XENE) moliyaviy va bozor koʻrsatkichlari kesimi

- kotirovkalar va tahlilchilar prognozi:
- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Kompaniyaning fundamental baholanishi:Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals tovar namunasi

Epilepsiyaga qarshi dori vositalari sohasidagi noyob patentlar tufayli Xenon Pharmaceuticals (XENE) narxlarning bosimidan himoyalangan, bu esa kelajakdagi foydalarga tikilgan garovni hal qiluvchi ahamiyatga ega qiladi. Kompaniyaning joriy prognoz qilingan P/E koeffitsiyentini tahlil qilish orqali investor Fed stavkalari bilan nisbatan bozorning rentabellik kutib-kutishlarini baholaydi, bunda koeffitsiyentning pasayishi aktivning qadrini past baholashni yoki sektorda likvidlik yetishmovchiligi xavfini anglatadi.

Toʻgʻridan-toʻgʻri raqobatchilar

Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori RGC (Regencell Bioscience Ltd)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forvard P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Kelajakdagi narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Kelajakdagi narxning foydaga nisbati|DNLI (denalitherapeutics.com) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati HRMY (Harmony Biosciences Holdings, Inc.)|Forvard P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Narxning kutilayotgan foydaga nisbati|anavex.com - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori CBLL (CeriBell, Inc.)|PRTA: Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ALEC|ANNX (Annexon Biosciences Inc.) - Forvard P/E multiplikatori|omeros.com - Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Neurogene (NGNE)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AC Immune SA|Forvard P/E multiplikatori VYGR (voyagertherapeutics.com)|Forvard P/E multiplikatori Neumora NMRA|Scilex Holding - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Kelajakdagi narxning foydaga nisbati|cogrx.com (CGTX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Assertio Therapeutics (ASRT)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Coya|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)